BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

148 related articles for article (PubMed ID: 35511739)

  • 1. SNPs at SMG7 Associated with Time from Biochemical Recurrence to Prostate Cancer Death.
    Song X; Ru M; Steinsnyder Z; Tkachuk K; Kopp RP; Sullivan J; Gümüş ZH; Offit K; Joseph V; Klein RJ
    Cancer Epidemiol Biomarkers Prev; 2022 Jul; 31(7):1466-1472. PubMed ID: 35511739
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Genome-wide Scan Identifies Role for AOX1 in Prostate Cancer Survival.
    Li W; Middha M; Bicak M; Sjoberg DD; Vertosick E; Dahlin A; Häggström C; Hallmans G; Rönn AC; Stattin P; Melander O; Ulmert D; Lilja H; Klein RJ
    Eur Urol; 2018 Dec; 74(6):710-719. PubMed ID: 30289108
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prognostic significance of prostate cancer susceptibility variants on prostate-specific antigen recurrence after radical prostatectomy.
    Huang SP; Huang LC; Ting WC; Chen LM; Chang TY; Lu TL; Lan YH; Liu CC; Yang WH; Lee HZ; Hsieh CJ; Bao BY
    Cancer Epidemiol Biomarkers Prev; 2009 Nov; 18(11):3068-74. PubMed ID: 19900942
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Susceptibility loci associated with prostate cancer progression and mortality.
    Gallagher DJ; Vijai J; Cronin AM; Bhatia J; Vickers AJ; Gaudet MM; Fine S; Reuter V; Scher HI; Halldén C; Dutra-Clarke A; Klein RJ; Scardino PT; Eastham JA; Lilja H; Kirchhoff T; Offit K
    Clin Cancer Res; 2010 May; 16(10):2819-32. PubMed ID: 20460480
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Impact of Downgrading from Biopsy Gleason 7 to Prostatectomy Gleason 6 on Biochemical Recurrence and Prostate Cancer Specific Mortality.
    Ham WS; Chalfin HJ; Feng Z; Trock BJ; Epstein JI; Cheung C; Humphreys E; Partin AW; Han M
    J Urol; 2017 Apr; 197(4):1060-1067. PubMed ID: 27847296
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Genetic predisposition to early recurrence in clinically localized prostate cancer.
    Borque Á; del Amo J; Esteban LM; Ars E; Hernández C; Planas J; Arruza A; Llarena R; Palou J; Herranz F; Raventós CX; Tejedor D; Artieda M; Simon L; Martínez A; Carceller E; Suárez M; Allué M; Sanz G; Morote J
    BJU Int; 2013 Apr; 111(4):549-58. PubMed ID: 22759231
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Prognostic Factors for Biochemical Recurrence More than 10 Years after Radical Prostatectomy.
    Liesenfeld L; Kron M; Gschwend JE; Herkommer K
    J Urol; 2017 Jan; 197(1):143-148. PubMed ID: 27418452
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Improved risk stratification for biochemical recurrence after radical prostatectomy using a novel risk group system based on prostate specific antigen density and biopsy Gleason score.
    Freedland SJ; Wieder JA; Jack GS; Dorey F; deKernion JB; Aronson WJ
    J Urol; 2002 Jul; 168(1):110-5. PubMed ID: 12050502
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Impact of positive surgical margins on prostate-specific antigen failure after radical prostatectomy in adjuvant treatment-naïve patients.
    Ploussard G; Agamy MA; Alenda O; Allory Y; Mouracade P; Vordos D; Hoznek A; Abbou CC; de la Taille A; Salomon L
    BJU Int; 2011 Jun; 107(11):1748-54. PubMed ID: 20883488
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Time to prostate specific antigen recurrence after radical prostatectomy and risk of prostate cancer specific mortality.
    Freedland SJ; Humphreys EB; Mangold LA; Eisenberger M; Partin AW
    J Urol; 2006 Oct; 176(4 Pt 1):1404-8. PubMed ID: 16952644
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The EGFR polymorphism rs884419 is associated with freedom from recurrence in patients with resected prostate cancer.
    Perez CA; Chen H; Shyr Y; Courtney R; Zheng W; Cai Q; Hwang M; Jaboin J; Schleicher S; Moretti L; Wills M; Smith JA; Lu B
    J Urol; 2010 May; 183(5):2062-9. PubMed ID: 20303520
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Genetic interaction analysis of TCF7L2 for biochemical recurrence after radical prostatectomy in localized prostate cancer.
    Chen CS; Huang CY; Huang SP; Lin VC; Yu CC; Chang TY; Bao BY
    Int J Med Sci; 2015; 12(3):243-7. PubMed ID: 25678841
    [TBL] [Abstract][Full Text] [Related]  

  • 13. A common regulatory variant in SLC35B4 influences the recurrence and survival of prostate cancer.
    Huang EY; Chang YJ; Huang SP; Lin VC; Yu CC; Huang CY; Yin HL; Chang TY; Lu TL; Bao BY
    J Cell Mol Med; 2018 Jul; 22(7):3661-3670. PubMed ID: 29682886
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The Role of Prostate-specific Antigen Persistence After Radical Prostatectomy for the Prediction of Clinical Progression and Cancer-specific Mortality in Node-positive Prostate Cancer Patients.
    Bianchi L; Nini A; Bianchi M; Gandaglia G; Fossati N; Suardi N; Moschini M; Dell'Oglio P; Schiavina R; Montorsi F; Briganti A
    Eur Urol; 2016 Jun; 69(6):1142-8. PubMed ID: 26749093
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Biochemical (prostate specific antigen) recurrence probability following radical prostatectomy for clinically localized prostate cancer.
    Han M; Partin AW; Zahurak M; Piantadosi S; Epstein JI; Walsh PC
    J Urol; 2003 Feb; 169(2):517-23. PubMed ID: 12544300
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Stratification of patient risk based on prostate-specific antigen doubling time after radical retropubic prostatectomy.
    Tollefson MK; Slezak JM; Leibovich BC; Zincke H; Blute ML
    Mayo Clin Proc; 2007 Apr; 82(4):422-7. PubMed ID: 17418069
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Radical prostatectomy for incidental (stage T1a-T1b) prostate cancer: analysis of predictors for residual disease and biochemical recurrence.
    Capitanio U; Scattoni V; Freschi M; Briganti A; Salonia A; Gallina A; Colombo R; Karakiewicz PI; Rigatti P; Montorsi F
    Eur Urol; 2008 Jul; 54(1):118-25. PubMed ID: 18314255
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Prostate cancer-specific survival following salvage radiotherapy vs observation in men with biochemical recurrence after radical prostatectomy.
    Trock BJ; Han M; Freedland SJ; Humphreys EB; DeWeese TL; Partin AW; Walsh PC
    JAMA; 2008 Jun; 299(23):2760-9. PubMed ID: 18560003
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Prognostic Value of Biochemical Recurrence Following Treatment with Curative Intent for Prostate Cancer: A Systematic Review.
    Van den Broeck T; van den Bergh RCN; Arfi N; Gross T; Moris L; Briers E; Cumberbatch M; De Santis M; Tilki D; Fanti S; Fossati N; Gillessen S; Grummet JP; Henry AM; Lardas M; Liew M; Rouvière O; Pecanka J; Mason MD; Schoots IG; van Der Kwast TH; van Der Poel HG; Wiegel T; Willemse PM; Yuan Y; Lam TB; Cornford P; Mottet N
    Eur Urol; 2019 Jun; 75(6):967-987. PubMed ID: 30342843
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Genetic variants in microRNAs and microRNA target sites predict biochemical recurrence after radical prostatectomy in localized prostate cancer.
    Huang SP; Lévesque E; Guillemette C; Yu CC; Huang CY; Lin VC; Chung IC; Chen LC; Laverdière I; Lacombe L; Fradet Y; Chang TY; Lee HZ; Juang SH; Bao BY
    Int J Cancer; 2014 Dec; 135(11):2661-7. PubMed ID: 24740842
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.